Share Price | Apollomics, Inc. Stock Analysis & Recommendation

Q: What does Apollomics, Inc. do?

Overview: Apollomics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: 0 Million (Quarterly Results - Sep 2022) Market cap: USD 7.01 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.96 Return on Equity: -848.64% Price to Book: 1.44Contact Details: Registrar Address: Not available.

Q: Is Apollomics, Inc. technically bullish or bearish?

As of 29 August 2025, the technical trend for Apollomics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bearish on the weekly and shows no signal on the monthly. The moving averages indicate a mildly bearish trend on the daily. Additionally, the Bollinger Bands are bullish weekly but mildly bearish monthly, and the KST is bullish weekly but bearish monthly. Despite the mildly bearish outlook, the stock has significantly outperformed the S&P 500 over the past week (190.79% vs. 1.05%) and month (217.46% vs. 2.33%).

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.94 k

Shareholding (Jun 2025)

FII

0.06%

Held by 3 FIIs

DII

91.04%

Held by 1 DIIs

Promoter

7.78%

How big is Apollomics, Inc.?

22-Jun-2025

As of Jun 18, Apollomics, Inc. has a market capitalization of 7.01 million and reported net sales of 0.00 million with a net profit of -0.83 million over the last four quarters. The balance sheet shows shareholder's funds of 4.86 million and total assets of 13.10 million.

View full answer

What does Apollomics, Inc. do?

22-Jun-2025

Apollomics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting no net profit and a market cap of $7.01 million. Key financial metrics indicate it is loss-making with a negative return on equity and no dividend yield.

View full answer

Is Apollomics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 29, 2025, Apollomics, Inc. shows a mildly bearish trend overall, with mixed technical indicators, including a mildly bullish MACD and bearish RSI, while significantly outperforming the S&P 500 in the past week and month.

View full answer

Compare Apollomics, Inc. with Similar Stocks

Aligos Therapeutics, Inc.ASP Isotopes, Inc.Checkpoint Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 21 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.43

Return on Equity

938.56%

Price to Book

-4.86

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2022)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

158.01%

6 Months

172.07%

1 Year

-15.71%

2 Years

-96.11%

3 Years

-98.07%

4 Years

0.0%

5 Years

0.0%

Apollomics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-21.95%

EBIT to Interest (avg)

-11.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.96

Sales to Capital Employed (avg)

Tax Ratio

0.48%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.08%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.49

EV to EBIT

0.05

EV to EBITDA

0.05

EV to Capital Employed

0.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

906.70%

ROE (Latest)

-848.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (1.11%)

Foreign Institutions

Held by 3 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Apollomics, Inc."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.77% vs 28.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.00",
          "val2": "-54.10",
          "chgp": "22.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-12.60",
          "val2": "-74.00",
          "chgp": "82.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.90",
          "val2": "-172.60",
          "chgp": "68.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-42.00

-54.10

22.37%

Interest

0.20

Exceptional Items

-12.60

-74.00

82.97%

Consolidate Net Profit

-53.90

-172.60

68.77%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.77% vs 28.32% in Dec 2023

All Annual Results

Company CV

About Apollomics, Inc.

Apollomics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Apollomics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Apollomics, Inc.?

Watch in Real-Time

What does Apollomics, Inc. do?

Is Apollomics, Inc. technically bullish or bearish?

Compare Apollomics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Annual Results Snapshot (Consolidated) - Dec'24

About Apollomics, Inc.

Company Coordinates